Case Report : Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report

Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of gynecologic oncology Vol. 21; no. 4; pp. 269 - 272
Main Authors:	Ye Won Chung, Hyo Sook Bae, Song I Han, Jae Yoon Song, In Sun Kim, Jae Seong Kang
Format:	Journal Article
Language:	Korean
Published:	대한부인종양학회 30-12-2010
Subjects:	Breast cancer Mullerian adenofibroma Mullerian adenosarcoma Tamoxifen Toremifene
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.
Bibliography:	Korean Society of Gynecologic Oncology
ISSN:	2005-0380